Art. -Nr.: HY-10451

Canagliflozin

(Synonyms: JNJ 28431754)

47 Cited Publications

Kundenbewertung

Based on 47 publication(s) in Google Scholar

Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.99%
CAS. Nr.: 842133-18-0
Formel: C₂₄H₂₅FO₅S
Molecular Weight:444.52

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Canagliflozin Chemical Structure

CAS. Nr.: 842133-18-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (47)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively^[1].

IC₅₀ & Target

SGLT2

Alle SGLT Isoform-spezifische Produkte anzeigen :

SGLT1
SGLT2

Cellular Effect

Cell Line	Type	Value	Description	References
CHO-K1	IC₅₀	1900 nM Compound: 4	Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay	[PMID: 22652255]
CHO-K1	IC₅₀	6.7 nM Compound: 4	Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay	[PMID: 22652255]

In Vitro

Canagliflozin inhibits Na⁺-dependent ¹⁴C-AMG uptake in CHO-hSGLT2 cells, with an IC₅₀ of 4.4±1.2 nM. Similar IC₅₀ values are obtained in CHO-rSGLT2 and CHO-mSGLT2 cells (IC₅₀ = 3.7 and 2.0 nM for rat and mouse SGLT2, respectively). Canagliflozin inhibits ¹⁴C-AMG uptake in CHO-hSGLT1 and mSGLT1 cells with IC₅₀ of 684±159 nM and >1,000 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Canagliflozin (30 mg/kg treatment for 4 weeks) reduces blood glucose (BG) levels, respiratory exchange ratio, and body weight gain in DIO mice^[1].
Canagliflozin (3 mg/kg for 3 weeks) increases urinary glucose excretion (UGE) with no significant change in total food intake compared with that in vehicle-treated rats, leading to a decrease in body weight In ZF rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Diet-induced obese, insulin resistantmice (DIO) Mice^[1]
Dosage:

30 mg/kg
Administration:

Oral gavage; daily; 4 weeks
Result:

Reduced BG levels, respiratory exchange ratio, and body weight gain.

Animal Model:

Male Zucker fatty (ZF) obese, insulin resistant rats^[1]
Dosage:

3 mg/kg
Administration:

Oral gavage; daily; 3 weeks
Result:

UGE was increased with no significant change in total food intake compared with that in vehicle-treated rats, leading to a decrease in body weight.

Chemical Information

CAS. Nr. 842133-18-0
Appearance Solid
Molecular Weight 444.52
Formel C₂₄H₂₅FO₅S
Color White to light yellow
SMILES

FC1=CC=C(C2=CC=C(CC3=C(C=CC([C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)=C3)C)S2)C=C1
Synonyms

JNJ 28431754
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (47)

All WB

Sort by:

Journal Impact Factor

Nature

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. [Abstract]

2018 Aug;560(7719):499-503. PMID: 30051890
Nat Cancer

Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation. [Abstract]

2024 Mar;5(3):433-447. PMID: 38286827
Nat Cell Biol

Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. [Abstract]

2022 Jun;24(6):954-967. PMID: 35637408
Nat Commun

IDH2 lactylation promotes angiogenesis in murine diabetic myocardial infarction via blocking Cav1-eNOS interaction. [Abstract]

2025 Dec 19. PMID: 41419771
Mol Cell

Cell-Autonomous versus Systemic Akt Isoform Deletions Uncovered New Roles for Akt1 and Akt2 in Breast Cancer. [Abstract]

2020 Oct 1;80(1):87-101.e5. PMID: 32931746
Cardiovasc Res

SGLT2 inhibitor canagliflozin alleviates vascular calcification through suppression of NLRP3 inflammasome. [Abstract]

2023 Oct 24;119(13):2368-2381. PMID: 37523743
Cardiovasc Res

Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart. [Abstract]

2021 Dec 17;117(14):2794-2806. PMID: 33135077
Cell Commun Signal

Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes. [Abstract]

2024 Nov 7;22(1):534. PMID: 39511548
Arch Toxicol

Canagliflozin differentially modulates carfilzomib-induced endoplasmic reticulum stress in multiple myeloma and endothelial cells. [Abstract]

2025 Feb;99(2):729-744. PMID: 39645617
Acta Pharmacol Sin

SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. [Abstract]

2024 Dec;45(12):2579-2597. PMID: 39294445
Diabetes

Canagliflozin-induced adaptive metabolism in bone. [Abstract]

2025 Feb 11:db240955. PMID: 39932694
Antioxidants (Basel)

Canagliflozin Inhibits Palmitic Acid-Induced Vascular Cell Aging In Vitro through ROS/ERK and Ferroptosis Pathways. [Abstract]

2024 Jul 11;13(7):831. PMID: 39061899
Antioxidants (Basel)

Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway. [Abstract]

2023 Mar 30;12(4):838. PMID: 37107212
Neurotherapeutics

2023 Dec 19, e00305.
Int J Oncol

Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A. [Abstract]

2020 Nov;57(5):1223-1233. PMID: 32901837
Biochem Pharmacol

Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin. [Abstract]

2020 May;175:113856. PMID: 32061772
Biochem Pharmacol

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. [Abstract]

2018 Jun:152:45-59. PMID: 29551587

Canagliflozin purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Jun:152:45-59. [Abstract]

Effects of NF-κB inhibitor (10 μM MLN120B) is measured on p62 protein in LPS-induced RAW264.7 cells.

Canagliflozin purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Jun:152:45-59. [Abstract]

PFK2 expression is significantly increased by LPS but is attenuated by Canagliflozin (CAN).
J Am Heart Assoc

Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling. [Abstract]

2022 Aug 2;11(15):e025328. PMID: 35904193
Commun Biol

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. [Abstract]

2023 Sep 8;6(1):919. PMID: 37684337
Can J Cardiol

Canagliflozin Alleviates Pressure Overload-Induced Cardiac Dysfunction via PINK1 Regulation by Inhibiting Mitophagy-Driven Ferroptosis. [Abstract]

2026 Apr 24:S0828-282X(26)00372-7. PMID: 42035950
Int J Mol Sci

Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Fibroblast Properties. [Abstract]

2025 Oct 16;26(20):10098. PMID: 41155391
Int J Mol Sci

Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. [Abstract]

2025 Jan 24;26(3):978. PMID: 39940750
Int J Mol Sci

SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice. [Abstract]

2024 Jul 10;25(14):7567. PMID: 39062810
Int Immunopharmacol

Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization. [Abstract]

2020 Nov;88:106969. PMID: 33182027
Front Pharmacol

Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells. [Abstract]

2025 Apr 30:16:1573032. PMID: 40371351
Mol Med Rep

Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin‑induced cardiotoxicity in rats. [Abstract]

2021 Oct;24(4):703. PMID: 34368866
Sci Rep

Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK. [Abstract]

2021 Jul 1;11(1):13700. PMID: 34211080
Mol Oncol

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. [Abstract]

2023 Nov;17(11):2235-2256. PMID: 37584455
Biochim Biophys Acta Mol Cell Res

Canagliflozin inhibits p38MAPK signaling to protect tubular epithelial cell against pyroptosis in sepsis-induced acute kidney injury. [Abstract]

2025 Oct 12;1873(1):120069. PMID: 41086994
FASEB J

Deubiquitinase OTUD4 Stabilizes SLC5A2 to Promote Pancreatic Cancer Proliferation and Migration Through Enchaining Glycolysis-Mediated Autophagy. [Abstract]

2025 Jul 31;39(14):e70880. PMID: 40719816
FASEB J

Canagliflozin Delays Aortic Valve Calcification by Enhancing the AMPK/Nrf2/HO-1 Antioxidant Signaling Pathway in Valvular Interstitial Cells. [Abstract]

2025 May 31;39(10):e70630. PMID: 40357866
Vascul Pharmacol

Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. [Abstract]

2018 Oct:109:56-71. PMID: 29908295
Int J Med Sci

Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. [Abstract]

2018 Jun 13;15(9):937-943. PMID: 30008607
J Diabetes Investig

Canagliflozin protects cardiovascular function in type 2 diabetic coronary artery disease by regulating natriuretic peptide B. [Abstract]

2025 Aug;16(8):1430-1444. PMID: 40390212
Calcif Tissue Int

Effect of Canagliflozin Pretreatment on the Efficacy of Insulin Therapy to Rescue Type 1 Diabetes-Related Bone Fragility in Male Mice. [Abstract]

2026 Jan 31;117(1):20. PMID: 41618015
Mol Cell Endocrinol

Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease. [Abstract]

2024 Mar 1:582:112139. PMID: 38128823
Biochem Biophys Res Commun

Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress. [Abstract]

2023 Apr 23:653:53-61. PMID: 36857900
Biomed Chromatogr

A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. [Abstract]

2019 Nov;33(11):e4663. PMID: 31339572
Biomed Chromatogr

A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. [Abstract]

2016 Oct;30(10):1549-55. PMID: 26989857
University of Porto

2025.
University of Porto

2025.
Patent

US20210236501A1.
Biomed Pharmacother

Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes. [Abstract]

2024 Jun 27:177:117044. PMID: 38941892
Research Square Preprint

2023 Dec 28.
Biomed Pharmacother

Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. [Abstract]

2023 Aug:164:114907. PMID: 37247463
Biomed Pharmacother

Canagliflozin inhibits inflammasome activation in diabetic endothelial cells - Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells. [Abstract]

2023 Mar:159:114228. PMID: 36623448
Biomed Pharmacother

Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. [Abstract]

2020 Dec;132:110821. PMID: 33068934

Canagliflozin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Dec;132:110821. [Abstract]

MCF-7 and ZR-75-1 cells are exposed to Canagliflozin 0, 11, 33, and 100 μM for 24 h and protein levels of p-AMPK, total AMPK, p-p70S6K1 and total p70S6K1 are detected using immunoblot assay.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (112.48 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2496 mL

11.2481 mL

22.4962 mL

5 mM

0.4499 mL

2.2496 mL

4.4992 mL

10 mM

0.2250 mL

1.1248 mL

2.2496 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (5.62 mM); Clear solution

Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.62 mM); Clear solution

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 6

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: ≥ 0.5 mg/mL (1.12 mM); Clear solution

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (22.50 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (580 KB)
- English - EN (580 KB)
- Français - FR (580 KB)
- Deutsch - DE (580 KB)
- Norwegian - NO (580 KB)
- Español - ES (580 KB)
- Swedish - SV (580 KB)
- Italian - IT (580 KB)
- Korean - KR (580 KB)
- Portuguese - PT (580 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Matsuda H, et al. Roles of capsaicin-sensitive sensory nerves, endogenous nitric oxide, sulfhydryls, and prostaglandins in gastroprotection by momordin Ic, an oleanolic acid oligoglycoside, on ethanol-induced gastric mucosal lesions in rats. Life Sci. 1999;65(2):PL27-32. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2496 mL	11.2481 mL	22.4962 mL	56.2404 mL
	5 mM	0.4499 mL	2.2496 mL	4.4992 mL	11.2481 mL
	10 mM	0.2250 mL	1.1248 mL	2.2496 mL	5.6240 mL
	15 mM	0.1500 mL	0.7499 mL	1.4997 mL	3.7494 mL
	20 mM	0.1125 mL	0.5624 mL	1.1248 mL	2.8120 mL
	25 mM	0.0900 mL	0.4499 mL	0.8998 mL	2.2496 mL
	30 mM	0.0750 mL	0.3749 mL	0.7499 mL	1.8747 mL
	40 mM	0.0562 mL	0.2812 mL	0.5624 mL	1.4060 mL
	50 mM	0.0450 mL	0.2250 mL	0.4499 mL	1.1248 mL
	60 mM	0.0375 mL	0.1875 mL	0.3749 mL	0.9373 mL
	80 mM	0.0281 mL	0.1406 mL	0.2812 mL	0.7030 mL
	100 mM	0.0225 mL	0.1125 mL	0.2250 mL	0.5624 mL

Keywords

Canagliflozin

47 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Canagliflozin

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Canagliflozin

Alle SGLT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (47)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Canagliflozin

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Canagliflozin

Alle SGLT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (47)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Canagliflozin Related Classifications

HY-10451 Related Classifications